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Endothelial injury in rheumatoid arthritis: a
crosstalk between dimethylarginines and
systemic inflammation
Theodoros Dimitroulas1,2*, James Hodson3, Aamer Sandoo4, Jacqueline Smith2 and George D. Kitas5
Abstract
Background: Symmetric (SDMA) and asymmetric (ADMA) dimethylarginines have emerged as novel biomarkers of
cardiovascular disease (CVD) in several disease settings associated with atherosclerosis. Rheumatoid arthritis (RA) is a
chronic systemic inflammatory disease characterized by high CVD mortality and morbidity. ADMA and SDMA levels
are abnormal in RA patients, but their correlation with assessments of endothelial function and structure remains
unknown. We aimed to investigate whether SDMA and ADMA are associated with carotid intima media thickness
(cIMT) and arterial stiffness as well as non-invasive assessments of in vivo micro- and macrovascular endothelial
function in RA patients with high systemic inflammatory load.
Method: ADMA and SDMA levels were measured using immunoassays in 197 RA individuals. Twenty-six of these
[23 (86.4%) females, median age 70, quartiles (60, 73)] were identified as having high inflammatory markers
[erythrocyte sedimentation rate (ESR) >25 mm/hr and C-reactive protein (CRP) > 5 mg/L], and were compared to
the remainder of the cohort. Patients underwent assessments of microvascular endothelium-dependent and
endothelium-independent function [laser Doppler imaging with iontophoresis of acetylcholine (Ach) and sodium-
nitroprusside (SNP) respectively], macrovascular endothelium-dependent and endothelium-independent function
(flow-mediated dilatation and glyceryl-trinitrate-mediated dilation respectively), and vascular morphology [pulse
wave analysis, and carotid intima media thickness (cIMT)].
Results: Significant interactions with inflammation were detected in the associations between ACh and both SDMA
(p = 0.014) and ADMA:SDMA ratio (p = 0.027), as well as between SNP and SDMA (p = 0.042) and between arterial
stiffness and ADMA:SDMA (p = 0.036), with the associations being stronger in the patients with high inflammatory
markers in each case.
Conclusions: Besides their emerging role as markers of endothelial dysfunction SDMA and ADMA may promote
endothelial injury in RA as mediators of the adverse effects of systemic inflammation on micro- and
macrovasculature respectively in patients with active disease.
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Background
Patients with rheumatoid arthritis (RA) have an increased
risk for cardiovascular disease (CVD), which appears to be
of equal frequency and severity to those with diabetes
mellitus of similar duration [1]. This elevated CVD risk is
only partially explained by the higher prevalence of trad-
itional CVD risk factors in RA [2] and accounts for almost
40–50% of all deaths resulting in premature mortality and
reduced life expectancy amongst RA patients compared to
the general population [3]. The precise pathogenic mecha-
nisms of CVD remain partially understood. It appears that
inflammation-induced accelerated atherosclerosis is the
main contributor to the excess CVD risk in RA, as inflam-
matory processes in rheumatoid synovia and atheroscler-
otic plaque share striking similarities [4].
Derangement of endothelial function is a key early step
in the initiation of vascular injury leading to accelerated
atherosclerosis and the development of plaque. Nitric
oxide (NO) is the main endothelium-derived regulator of
vascular homeostasis with vasodilatory, anti-proliferative
and anti-atherogenic properties [5]. Reduced NO synthesis
and bioavailability can lead to endothelial dysfunction
through several mechanisms such as loss of basal vaso-
dilator tone, enhanced blood cell migration and raised
local chemokine and/or cytokine release. In RA, systemic
inflammation is a pivotal player in the disruption of the
equilibrium between the production of NO and other
vasoactive agents and the ensuing imbalance initiates
platelet activation, abnormal fibrinolytic activity, lipid and
glucose metabolism disorders as well as oxidative stress,
all of which contribute to impaired vascular patency and a
hypercoagulable state [6–8]. There is a continuous need
for the investigation of potential pathogenetic pathways
that may shed more light in the complex interrelations
between vascular dysfunction and systemic inflammation
in RA.
Recently, interest has shifted towards the identification
of molecules associated with suppression of NO syn-
thase activity, the enzyme responsible for NO synthesis.
Asymmetric (ADMA) and symmetric (SDMA) dimethy-
larginines are analogues of L-arginine - the precursor of
NO - naturally liberated in biological fluids following pro-
teolysis. They inhibit NO synthesis by competing with L-
arginine at the active site of NO synthase. Regulation of
ADMA metabolism depends on the enzymatic activity of
dimethylarginine dimethylaminohydrolase whilst SDMA
is mainly cleaved by kidneys, with ADMA:SDMA ratio
suggested as an index of dimethylarginine dimethylamino-
hydrolase activity [9]. Dimethylarginines have emerged as
novel markers of endothelial dysfunction and CVD risk in
several conditions associated with severe vascular disease,
such as coronary artery disease [10], renal failure [11],
diabetes mellitus [12] as well as in the general population
[13]. A recent meta-analysis of 22 prospective studies
suggested that ADMA is strongly associated with CVD
outcomes in a broad range of circumstances [14],
confirming previous reports and illustrating a role for
dimethylarginines in the assessment of CVD risk in high-
risk populations. In RA, we and others have demonstrated
abnormal circulating levels of ADMA and SDMA and
established robust correlations with other indices of ath-
erosclerotic burden, namely insulin resistance and cumu-
lative systemic inflammatory load [15–18]. In RA, ADMA
has been associated with morphological markers of sub-
clinical atherosclerosis, such as carotid intima-media
thickness (cIMT) in some [19] but not all studies [15, 20].
Published data employing non-invasive techniques of
endothelium-dependent and endothelium-independent
peripheral micro- and macrovascular function and pulse
wave analysis have failed to establish relationships be-
tween dimethylargines and measurements of vascular
morphology [21]. However, most of these studies included
unselected RA patients with a mixture of high, moderate,
low and/or minimal disease activity. Although endothelial
function and structure are affected in patients with RA
[22], no clear association between vascular abnormalities
and systemic inflammation has been demonstrated [23].
The aim of the current study was to address whether
dimethylarginine levels correlate with structural and
functional markers of atherosclerosis specifically in RA
patients with high systemic inflammatory load.
Methods
Patient characteristics
One hundred and ninety-seven consecutive patients
were recruited from the Dudley Rheumatoid Arthritis
Co-morbidity Cohort (DRACCO), a prospective study
examining CV burden in RA. Detailed characteristics of
the participants have been described previously [17]. Ex-
clusion criteria included confirmed acute coronary syn-
drome, evidence of chronic kidney disease or serious
psychiatric disorders. The study received ethics approval
from The Black Country Research Ethics Committee
and all participants gave their written informed consent
according to the Declaration of Helsinki. In the present
study, RA patients with high inflammatory markers de-
fined as erythrocyte sedimentation rate (ESR) > 25 mm/
hr and C-reactive protein (CRP) > 5 mg/L were identified
and analysed as a distinct group. Comparisons were per-
formed between the two subgroups of RA patients: the
one with high inflammatory markers and the remaining
patients with normal values of ESR and CRP.
Protocol
All patients reported to a thermoregulated (22 ± 0.9 °C)
vascular laboratory after a 12-hour overnight fast. They
were asked to refrain from exercise 24 hours before the
session, and from smoking 12 hours before the session.
Dimitroulas et al. Arthritis Research & Therapy  (2017) 19:32 Page 2 of 10
Drug regimens were not interrupted. All participants
underwent a detailed clinical examination and demo-
graphic information was collected by questionnaire. A
blood sample was also obtained on the same day, for the
assessments of routine hematologic and biochemistry,
lipid profile, fasting glucose, fasting insulin, and acute
phase response. ESR was measured using the Starrsed
Auto Compact blood sedimentation instrument, which
automatically carries out the erythrocyte sedimentation
analysis according to the Westergren reference method.
CRP was measured using the VITROS™ 5,1 FS Chemistry
System (Ortho-Clinical Diagnostics, Raritan, NJ, USA).
This is an immunoturbidimetric method. The antibody in
the reagent combines with CRP in the specimen thereby
increasing turbidity in the solution. This is measured as
an increase in absorbance at 340 nm. The identification of
patients with high/abnormal inflammatory markers (ESR >
25 mm/hr and CRP > 5 mg/L) was performed on the basis
of the upper limits of normal as provided by the lab. All
biochemical tests were carried out in the Biochemistry
Laboratory at Russells Hall Hospital, The Dudley Group
NHS Foundation Trust, UK.
Microvascular endothelial function
Endothelial function of the microvasculature was
assessed non-invasively using laser Doppler imaging
(LDI) (Moor laser Doppler imager, Moor Instruments
Ltd, Axminster, UK) with iontophoresis of 1% acetylcho-
line (ACh, endothelium-dependent, Miochol-E, Novartis,
Camberley, UK) and 1% sodium-nitroprusside (SNP,
endothelium-independent, Nitroprussiat Fides, Rotta-
pharm, Barcelona, Spain) in 2.5 ml solution containing
0.5% saline by a single observer (AS). This technique has
an intra-observer co-efficient of variation for ACh and
SNP of 6.5% and 5.9% respectively for AS [24].
Macrovascular endothelial function
Assessment of macrovascular endothelium-dependent
function was performed using flow-mediated dilatation
(FMD) with high-resolution ultrasonography of the
brachial artery (Acuson Antares ultrasound system, Siemens
PLC, Camberley, UK) according to previously established
guidelines [25]. The intra-observer co-efficient of variation
for the study ultrasonographer (AS) was 10.7% for flow-
mediated dilatation (FMD) and 11.8% for glyceryl-trinitrate-
mediated dilatation (GTN) assessments respectively. For all
vascular tests, endothelial function was expressed as the per-
centage increase in perfusion or diameter from baseline, and
all analysis was carried out offline by AS, who was blinded
to the identity of the patient.
Carotid atherosclerosis
High-resolution ultrasonography of the carotid artery
was performed by an experienced ultrasonographer (AS)
according to previously established guidelines [26]. The
cIMT was defined by determining the thickness between
the lines of Pignoli; with the first echogenic line repre-
senting the lumen-intima interface, and the second line
representing the media-adventitia interface [27]. Assess-
ments of cIMT were performed in the far wall, 1 cm
proximal to the carotid bulb, at sites free of plaque in
both the right and left common carotid arteries, using
the longitudinal scanning plane. Three measurements
were taken on each side, and these were averaged to give
the mean cIMT for the right and left carotid arteries
separately. The cIMT from both sides were further
averaged to give the overall cIMT. The intra-observer
co-efficient of variation was 8.6%.
Pulse wave analysis
Pulse wave analysis (SphygmoCor Px Pulse Wave Ana-
lysis, ScanMed Medical Instruments, Moreton-in-Marsh,
UK) was used to determine subendocardial viability ratio
(SEVR) and augmentation index (AIx) as described
previously [28]. Briefly, an applanation tonometer was
positioned over the radial artery with enough pressure
to flatten (but not occlude) the patient’s artery. The
applanation tonometer detects the pulse pressure wave,
which is calibrated against the standard brachial blood
pressure and gives the maximum (systolic) and mini-
mum (diastolic) points of the pressure wave. The pres-
sure waveform is then mathematically transformed into
a central aortic waveform, which contains the first (peak
flow) and second (peak pressure) systolic peaks and dis-
plays information on ejection duration. SEVR is calcu-
lated by utilising the ejection duration, which is
automatically measured by the Sphygmocor system, and
dividing the area under the diastolic curve (coronary
perfusion) by the area under the systolic curve (cardiac
workload). In normal conditions, SEVR can be anywhere
between 130% and 200%. Values that are below unity
(100%) reflect poor perfusion of the subendocardium.
Measurement of ADMA and SDMA
ADMA levels were measured in serum samples by using
a commercial enzyme immunoassay ELISA kit (Immun-
diagnostik, Bensheim, Germany) as previously described
[17]. The intra-assay coefficient of variation was 7.6%.
The SDMA assay is based on the method of competitive
enzyme-linked immunoassays. The sample preparation in-
cludes the addition of a derivatization reagent for SDMA
coupling. During the incubation period, the target SDMA
in the sample competes with the SDMA derivative (tracer)
immobilised on the wall of the microtiter plates for the
binding of the polyclonal antibodies. The SDMA in the
sample displaces the antibodies out of the binding to the
tracer. Therefore, the concentration of the tracer-bound
antibody is inversely proportional to the SDMA
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concentration in the sample. The absorbance is measured
at 450 nm and patient samples are read from a standard
curve. The intra-assay standard deviation was 7.5% and
inter-assay was 6%. The lowest amount detected was
0.05 μmol/L.
Statistical analysis
Prior to the analysis, the distributions of all variables being
considered were assessed. Log2-transfomations were
applied to any variables found to be skewed, in order to
normalise the distributions and improve model fit. For
variables with negative values, a constant was added to all
cases before the log2-transfomation, to ensure that this
was calculable in all cases. There were several clear out-
liers in the SDMA measurements, which were excluded
from the main analysis, in order to produce reliable
models for the remaining cases.
Patients with high levels of inflammation were com-
pared to the group with normal inflammatory markers,
using t tests for normally distributed (or log-transformed)
variables, Mann–Whitney tests for variables that were not
normally distributed, and Fisher’s exact tests for dichot-
omous variables.
General linear models were then produced, in order to
assess how the relationships between ADMA and/or
SDMA and a range of factors differed by the degree of
inflammation. A dichotomous variable indicating the in-
flammation group (normal or high) was added as an in-
dependent variable in each model, along with the factor
being considered. An interaction term between these
variables was also included, to test whether the gradient
for the factor being considered differed between patients
with normal and high levels of inflammation.
Where significant interactions were detected, the
resulting models were plotted, in order to visualise how
the relationships between ADMA and/or SDMA and the
factor being considered differed by inflammation. The
coefficients from these models were also anti-logged and
converted into gradients, representing the percentage in-
crease in ADMA and/or SDMA for a unit increase in
the factor.
A sensitivity analysis was also performed, in order to
assess whether excluding the outliers had biased the
sample and influenced the conclusions. For the whole
cohort, Spearman’s correlation coefficients between the
factors and outcomes were produced separately for the
high and normal inflammation groups. The resulting co-
efficients were then compared, to highlight any cases
where the relationships between variables differed by the
level of inflammation.
All analyses were performed using IBM SPSS Statistics
22 (IBM Corp. Armonk, NY, USA). Missing data were
excluded on a per analysis basis and p < 0.05 was
deemed to be indicative of statistical significance.
Results
Patients, characteristics, outliers
Data were available for 197 RA individuals. After being
log2-transformed, SDMA was found to closely follow a
normal distribution, with the exception of 11 (6%)
patients with SDMA values >1. These outliers were ex-
cluded, in order to make parametric analysis valid, and
to prevent them from becoming excessively influential in
the analyses performed, leaving N = 186. Of these pa-
tients, 26 (14%) were identified as having high levels of
inflammation, as defined above.
Comparisons between the high and normal inflamma-
tion groups are reported in Table 1. With the exception of
disease activity score 28, which was found to be increased
in the high inflammation group as expected, none of the
other factors were found to differ significantly between
the two groups. Table 2 reports the p values from the
models used to test for interactions between inflammation
and the factors being considered. Significant interactions
with inflammation were detected in the associations be-
tween vasodilatory responses to acetylocholine (Ach) and
both SDMA (p = 0.014) and ADMA:SDMA ratio (p =
0.027), as well as between vasodilatory responses to 1%
sodium-nitroprusside (SNP) and SDMA (p = 0.042) and
between augmentation index (AIx) and ADMA:SDMA ra-
tio (p = 0.036). In each of these cases, it was found that
the associations between the factors and SDMA or
ADMA:SDMA ratio were stronger in the high inflamma-
tion group compared to the normal inflammation group
(Table 3).
Microvascular function
For those patients with normal inflammatory markers,
there was no significant association between ACh and
SDMA (p = 0.791). However, a significant negative cor-
relation was detected in patients with high levels of in-
flammation (p = 0.006) (Fig. 1a). In this cohort, a twofold
increase in ACh was found to be associated with a 16%
reduction in SDMA.
The relationship between ACh and ADMA:SDMA was
also non-significant in patients with normal levels of in-
flammation (p = 0.528). However, in patients with high
levels of inflammation, a twofold increase in ACh was
associated with a significant (p = 0.008) increase of 26%
in ADMA:SDMA (Fig. 1b).
SNP
No significant association between SNP and SDMA was
detected in the group of patients with normal inflamma-
tion levels (p = 0.778). However, in the patients with high
levels of inflammation, a significant negative correlation
was detected (p = 0.034), with SDMA found to decline
by 6.2% for each twofold increase in SNP (Fig. 2).
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Macrovascular function
No significant associations between dimethylarginines
and assessments of macrovascular endothelial function
were detected either in the group of patients with nor-
mal or in those with high levels of inflammatory
markers.
Arterial stiffness
No significant association between AIX and
ADMA:SDMA ratio was detected in the group of pa-
tients with normal inflammation levels (p = 0.827). How-
ever, in the patients with high levels of inflammation, a
significant positive correlation was detected (p = 0.033),
Table 1 Demographics and RA disease characteristics and surrogate markers of atherosclerosis and endothelial dysfunction in RA patients
Factor All patients Inflammation
N (N = 186) Normal (N = 160) High (N = 26) p value
Age (years)b 186 66 (59, 73)b 66 (58, 72) 70 (60, 73) 0.225
Female gender (%)a 186 144 (77.4%) 121 (75.6%) 23 (88.5%) 0.206
Disease duration (years)b 154 16 (11, 25)b 16 (11,25) 16 (12. 21) 0.692
RF (%)a 183 136 (74.3%) 114 (72.2%) 22 (88.0%) 0.137
Anti-CCP antibodies (%)a 181 115 (63.5%) 96 (61.5%) 19 (76.0%) 0.186
ESR (mm/h)b 181 11 (5, 22)b 9 (5, 16) 40 (30, 56) -
CRP (mg/L)b 186 3.0 (2.9, 8.0)b 2.9 (2.9, 4.5) 21.0 (13.0, 31.0) -
DAS 28c 181 3.14 (1.18)c 2.97 (1.10) 4.19 (1.12) <0.001
ADMA (μmol/L)d 181 0.56 (0.54–0.58)d 0.55 (0.53–0.57) 0.59 (0.56–0.63) 0.136
SDMA (μmol/L)d 186 0.46 (0.44–0.47)d 0.46 (0.45–0.47) 0.45 (0.41–0.50) 0.812
ADMA:SDMAd 181 1.22 (1.17–1.27)d 1.20 (1.15–1.25) 1.30 (1.17–1.46) 0.167
Arterial stiffnessc 165 33 (9)c 33 (9) 33 (8) 0.791
Microvascular endothelial dependent (ACh %)d 179 235 (207–265)d 244 (213–276) 184 (119–262) 0.145
Microvascular endothelial- independent (SNP %)d 179 116 (100–134)d 119 (102–138) 100 (60–159) 0.421
Macrovascular endothelial- dependent (FMD %)d 173 9.8 (8.8–10.8)d 9.9 (8.8–11.0) 9.0 (6.4–11.9) 0.554
Macrovascular endothelial- independent (GTN %)d 155 19.6 (18.2–21.1)d 19.7 (18.2–21.4) 18.9 (16.0–22.4) 0.715
cIMT (mm)d 157 0.68 (0.66–0.70)d 0.67 (0.65–0.70) 0.72 (0.67–0.79) 0.116
Bold p values are significant at p < 0.05
RA rheumatoid arthritis, RF rheumatoid factor, anti-CCP anti–citrullinated protein antibody, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS 28
disease activity score 28, ADMA asymmetric dimethylarginine, SDMA symmetric dimethylarginine, ACh acetylcholine, SNP sodium nitroprusside, FMD flow-mediated
dilatation, GTN glyceryl-trinitrate mediated dilatation, cIMT intima media thickness
aN (%), with p values from Fisher’s exact tests
bMedian (quartiles), with p values from Mann–Whitney tests
cMean (SD), with p values from t tests
dGeometric mean (95% CI), with p values from t tests on log-transformed data
Table 2 p values from general linear models
ADMA SDMA ADMA:SDMA
Factor Main Eff. Inflam. Int. Main Eff. Inflam. Int. Main Eff. Inflam. Int.
Log2ACh 0.390 0.954 0.636 0.008 0.030 0.014 0.007 0.093 0.027
Log2SNP 0.702 0.989 0.824 0.074 0.056 0.042 0.100 0.151 0.087
Log2FMD 0.363 0.767 0.677 0.420 0.097 0.092 0.174 0.138 0.110
Log2GTN 0.754 0.702 0.823 0.799 0.812 0.868 0.959 0.607 0.737
Log2cIMT 0.217 0.323 0.051 0.550 0.265 0.562 0.607 0.953 0.259
Log2SEVR 0.876 0.727 0.706 0.006 0.049 0.052 0.058 0.252 0.268
AIx (HR 75) 0.204 0.367 0.246 0.205 0.221 0.127 0.050 0.097 0.036
p values from general linear models, with three terms included in each model: Main Eff. – the main effect of the factor being considered, Inflam. – a binary
variable, stating whether a patient had high levels of inflammation (ESR > 25 and CRP > 5), Int. – an interaction term between Main Eff. and Inflam., testing
whether the relationship between the factor and outcome differs by the degree of inflammation. Bold p values are significant at p < 0.05
ADMA asymmetric dimethylarginine, SDMA symmetric dimethylarginine, ACh acetylcholine, SNP sodium nitroprusside, FMD flow-mediated dilatation, GTN glyceryl-
trinitrate mediated dilatation, cIMT intima media thickness, SEVR subendocardial viability ratio, AIx augmentation index, HR heart rate
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with ADMA:SDMA ratio found to increase by 1.6% for
each unit increase in AIx (Fig. 3).
Sensitivity analysis
A sensitivity analysis was performed on the whole cohort
without exclusions (N = 197, 28 [14%] with high levels of
inflammation). Since the outliers were now being in-
cluded in the data, it was not possible to produce valid
regression models, so a non-parametric approach was
used. Patients were split into normal and high inflamma-
tion groups, and Spearman’s correlation coefficients pro-
duced to assess the level of correlation between variables
(Table 4).
The results were consistent with the main analysis,
with significant negative correlations detected between
SDMA and both ACh and SNP in patients with high in-
flammation that were not observed in those with normal
inflammation. ADMA:SDMA ratio was found to be
significantly positively correlated with ACh and AIx in
patients with high inflammation, but not in those with
normal inflammation, as in the main analysis. The sensi-
tivity analysis additionally identified a significant nega-
tive correlation between cIMT and ADMA in patients
with high inflammation that was not present in those
with normal inflammation. This effect was not found to
be significant in the main analysis, although it only nar-
rowly missed significance, with p = 0.051.
Discussion
The main finding of our study is the establishment of
statistically significant relationships between circulating
dimethylargines and assessments of microvascular func-
tion and arterial stiffness in RA patients with high levels
of systemic inflammatory activity. To the best of our
knowledge, this is the first time that such associations
are reported in this population and our results may pro-
vide further insights in the complex interrelations be-
tween functional vascular changes, atherosclerosis and
inflammation in RA.
Several non-invasive techniques for the assessment of
endothelial morphology and function in micro- and
macrovasculature can examine the development of
premature atherosclerosis and provide useful informa-
tion regarding an individual’s CVD risk status, particu-
larly in clinical settings associated with excess CVD risk,
such as RA [29]. In this study, we utilized a broad range
of assessments to ensure the global evaluation of vascu-
lar function and morphology and investigate potential
relationships between indices of vascular health and sur-
rogate markers of endothelial dysfunction and systemic
inflammation.
Our findings suggest that dimethylarginines represent
not only biomarkers of endothelial dysfunction, but may
themselves be important mediators of disruption of vascu-
lar homeostasis in RA. Besides their inhibitory properties
on NO synthesis, dysregulated ADMA and SDMA metab-
olism may affect endothelial function through other
mechanisms independent of NO synthase inhibition such
as inflammation [30]. Under these circumstances,
dimethylarginines contribute to the precipitation of oxida-
tive stress by altering endothelial NO synthase activity,
switching it to a superoxide synthase [31, 32] and acting
as amplifiers, promoting vascular injury. This is in line
with previous observations, demonstrating links between
derangement of NO/ADMA pathway, oxidative stress and
inflammation in RA individuals [17, 33, 34].
The inverse correlation between SDMA and micro-
vascular function demonstrated in our study may look at
first glance fundamentally counterintuitive. However,
SDMA levels are lower in RA subjects compared to con-
trols [16] similarly to what occurs in diabetes mellitus
and insulin-resistant patients [35, 36]. It appears that
common mechanisms affecting intracellular migration of
endogenous dimethylarginines in RA and insulin resistance
are associated with atherosclerosis in both conditions [1].
Given that SDMA competitively inhibits ADMA for entry
into the cells, increased SDMA cellular uptake induced by
decreased insulin sensitivity [37] indirectly contributes to
raised serum ADMA levels and progression of vascular dis-
ease. This intriguing interaction could explain how lower
SDMA levels are associated with microvascular endothelium
dysfunction. Finally, the establishment of associations with
both endothelium-dependent and endothelium-independent
microvascular function suggests that particularly SDMA
Table 3 Results from general linear models for factors with significant interaction terms
Normal inflammation High inflammation
Outcome Factor Gradient p value Gradient p value
SDMA Log2ACh −0.7% (−5.6%, 4.5%) 0.791 −16.3% (−26.3%, −5.0%) 0.006
ADMA:SDMA Log2ACh 2.2% (−4.5%, 9.4%) 0.528 25.6% (6.1%, 48.7%) 0.008
SDMA Log2SNP 0.4% (−2.4%, 3.3%) 0.778 −6.2% (−11.5%, −0.5%) 0.034
ADMA:SDMA AIx (HR 75) −0.1% (−0.5%, 0.4%) 0.827 1.6% (0.1%, 3.1%) 0.033
Results are from the models reported in Table 2. Since the outcome variables of SDMA and ADMA:SDMA had been log-transformed prior to analysis, the resulting coefficients
were anti-logged, and converted into gradients representing the percentage increase in the outcome for a one unit increase in the factor. For the log-transformed factors, this is
equivalent to the change associated with a twofold increase in the untransformed factor. Bold p values are significant at p< 0.05
SDMA symmetric dimethylarginine, ACh acetylcholine, ADMA asymmetric dimethylarginine, SNP sodium nitroprusside, AIx augmentation index, HR heart rate
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induces NO depletion through NO synthase-dependent and
NO synthase -independent pathways.
Cross-sectional studies have indicated a possible time
lag between endothelial injury and structural wall dam-
age, as impairment of endothelial function occurs differ-
ently and in different vascular beds with microvascular
function affected earlier than the macrovascular one in
RA individuals [38–40]. Despite the cross-sectional
design of these studies, which cannot confirm temporal
relationships, it can be speculated that the reported as-
sociations between SDMA only with microvascular
function may underscore the role of dimethylarginines
in initiating endothelial damage under conditions where
high systemic inflammatory markers are present. On the
other hand, the correlations between ADMA and cIMT
indicate a role for endogenous NO synthase inhibitors in
the development of later stages of atherosclerosis in in-
dividuals with high levels of systemic inflammation,
which concurs with reports linking elevated CRP with
cIMT in RA population [41].
It is worth noting that, in the modern era, ‘Treat to Tar-
get’ strategies and biologic regimens have considerably
Fig. 1 a The relationship between ACh and SDMA. b The relationship between ACh and ADMA:SDMA. ACh acetylcholine, ADMA asymmetric
dimethylarginine, SDMA symmetric dimethylarginine
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reduced the proportion of patients with high disease activ-
ity, to the point that only about 10% of the individuals in
our cohort presented with high levels of systemic inflam-
mation and only seven with disease activity score 28 > 5.1.
The results of our study indicate that subpopulations ana-
lysis may unfold mechanisms more prominent in specific
subgroups of patients, for example those with high sys-
temic inflammation. Once more, these findings confirm
the effect of active disease on vasculature and emphasize
the need for more aggressive management of CVD risk in
this subpopulation. The clinical relevance of interventions
specifically targeting ADMA- and SDMA-related path-
ways in RA patients with high inflammatory activity re-
mains to be evaluated in future large studies focusing on
specific end points. A recent double-blind randomized
study demonstrated that supplementation of oral tetrahy-
drobiopterin - a cofactor for the production of NO down-
regulated by oxidative stress - improved FMD in a small
cohort of RA patients [42], providing the rationale for fur-
ther research.
The strengths and limitations of our study merit con-
sideration. Since the number of patients with high in-
flammation was small, the analyses performed had
relatively low statistical power, particularly for the inter-
action term in the model, which was the main focus of
the study. As a result, small but genuine differences be-
tween the two groups may have been missed. For these
reasons, it would be preferable to validate the findings
from this analysis in an external cohort, in order to en-
sure reliability of the conclusions. The other limitation
Fig. 3 The relationship between AIx and ADMA:SDMA. ADMA asymmetric dimethylarginine, AIx augmentation index, HR heart rate, SDMA
symmetric dimethylarginine
Fig. 2 The relationship between SNP and SDMA. SNP sodium nitroprusside, SDMA symmetric dimethylarginine
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was the requirement to exclude those patients with high
SDMA levels from the main analysis. Leaving these cases
in the data meant that they became influential outliers
in the models produced, resulting in poor model fit and
breaking the assumption of normally distributed resid-
uals. However, the sensitivity analysis performed on the
data returned consistent results, implying that any bias
introduced by excluding these patients had not funda-
mentally affected the conclusions of the study. Neverthe-
less, our study contains adequate functional assessments
and morphological measurements of vasculature in a
real-life population representative of ‘average’ RA
patients attending routine rheumatology clinics.
Conclusions
In conclusion, we demonstrated that microvascular
function, arterial stiffness and cIMT are associated with
circulating ADMA and SDMA levels in RA patients with
high inflammatory markers. Although CVD represents
an unresolved issue throughout the whole RA popula-
tion, it appears that high systemic uncontrolled inflam-
matory activity poses the higher risk for CVD events in
RA subjects in the short and long term. In that respect,
the present study suggests a possible pathway through
which high systemic inflammatory load exerts its dele-
terious effects on vascular wall by precipitating the inter-
action between dimethylarginines, and endothelial cells
and diminishing NO production directly or indirectly.
Dimethylarginines therefore, can be considered import-
ant mediators of endothelial dysfunction contributing to
the oxidative stress burden in the vasculature and the
development of CVD in this population.
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